ℕℤ 𝕚𝕞𝕞𝕦𝕟𝕚𝕤𝕒𝕥𝕚𝕠𝕟 𝕕𝕚𝕣𝕖𝕔𝕥𝕠𝕣 𝕒𝕤𝕤𝕦𝕣𝕖𝕤 𝕓𝕠𝕣𝕕𝕖𝕣 𝕨𝕠𝕣𝕜𝕖𝕣𝕤, 𝕡𝕦𝕓𝕝𝕚𝕔 𝕒𝕓𝕠𝕦𝕥 𝕤𝕒𝕗𝕖𝕥𝕪 𝕠𝕗 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖
ℕℤ 𝕚𝕞𝕞𝕦𝕟𝕚𝕤𝕒𝕥𝕚𝕠𝕟 𝕕𝕚𝕣𝕖𝕔𝕥𝕠𝕣 𝕒𝕤𝕤𝕦𝕣𝕖𝕤 𝕓𝕠𝕣𝕕𝕖𝕣 𝕨𝕠𝕣𝕜𝕖𝕣𝕤, 𝕡𝕦𝕓𝕝𝕚𝕔 𝕒𝕓𝕠𝕦𝕥 𝕤𝕒𝕗𝕖𝕥𝕪 𝕠𝕗 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖
/cloudfront-ap-southeast-2.images.arcpublishing.com/nzme/EKI4KVMWUNEQWUYXZYC5FRD2J4.jpg)
𝕋𝕙𝕖 𝕠𝕗𝕗𝕚𝕔𝕚𝕒𝕝 𝕣𝕠𝕝𝕝𝕠𝕦𝕥 𝕠𝕗 𝕥𝕙𝕖 ℙ𝕗𝕚𝕫𝕖𝕣/𝔹𝕚𝕠ℕ𝕋𝕖𝕔𝕙 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖 𝕙𝕒𝕤 𝕓𝕖𝕘𝕦𝕟 𝕥𝕠𝕕𝕒𝕪 𝕒𝕔𝕣𝕠𝕤𝕤 𝕄𝕀ℚ 𝕤𝕥𝕒𝕗𝕗 𝕚𝕟 𝔸𝕦𝕔𝕜𝕝𝕒𝕟𝕕.
A small group of 29 vaccinators were given their first vaccine yesterday as part of final preparations.
Director-General of Health Ashley Bloomfield said New Zealand has reached “a key stage in its pandemic response”.
A small group of 29 vaccinators were given their first vaccine yesterday as part of final preparations.
Director-General of Health Ashley Bloomfield said New Zealand has reached “a key stage in its pandemic response”.
.
.
“Vaccination of our hard-working and dedicated border staff marks a significant step forward – a milestone that protects those at greatest risk of those getting the virus and helping reduce the risk of it spreading into our communities,” he said.
“Today we have kicked off the largest immunisation programme in our history by vaccinating the first of our border workforce, a critical step in protecting everyone in Aotearoa."
He said the programme would be rolled out in Wellington next Monday and Christchurch on Wednesday.
Following this, about 12,000 of New Zealand’s border and MIQ workers would be vaccinated “over the coming weeks,” Bloomfield said.
Members of those workers’ households would be in line next, with plans for the wider public rollout later in the year currently being finalised, he said.
Director of New Zealand’s Immunisation Advisory Centre, Dr Nikki Turner, says she has faced questions over the past week from hundreds of border and MIQ staff over whether the vaccine will be effective.
“People keep saying this came too fast but the clinical steps in the development of this vaccine - New Zealand has waited appropriately until we have seen all the clinical trial data, right from the early stuff, through to the very large pivotal clinical trials which were on more than 40,000 people,” she said.
Turner says the clinical trials show it’s an incredibly high-performing vaccine.
“The effectiveness data is around 90-95 per cent which translates to be, that if you had 100 people given this vaccine, at least 90-95 of them when they were exposed to Covid, would not get symptomatic illness.”
Turner said because New Zealand wasn’t the first country to get the vaccine there has been time to wait for a few months to observe the real-world clinical data coming from around the world that the vaccine is “performing as it did in the clinical trials”.
“Vaccination of our hard-working and dedicated border staff marks a significant step forward – a milestone that protects those at greatest risk of those getting the virus and helping reduce the risk of it spreading into our communities,” he said.
“Today we have kicked off the largest immunisation programme in our history by vaccinating the first of our border workforce, a critical step in protecting everyone in Aotearoa."
He said the programme would be rolled out in Wellington next Monday and Christchurch on Wednesday.
Following this, about 12,000 of New Zealand’s border and MIQ workers would be vaccinated “over the coming weeks,” Bloomfield said.
Members of those workers’ households would be in line next, with plans for the wider public rollout later in the year currently being finalised, he said.
Director of New Zealand’s Immunisation Advisory Centre, Dr Nikki Turner, says she has faced questions over the past week from hundreds of border and MIQ staff over whether the vaccine will be effective.
“People keep saying this came too fast but the clinical steps in the development of this vaccine - New Zealand has waited appropriately until we have seen all the clinical trial data, right from the early stuff, through to the very large pivotal clinical trials which were on more than 40,000 people,” she said.
Turner says the clinical trials show it’s an incredibly high-performing vaccine.
“The effectiveness data is around 90-95 per cent which translates to be, that if you had 100 people given this vaccine, at least 90-95 of them when they were exposed to Covid, would not get symptomatic illness.”
Turner said because New Zealand wasn’t the first country to get the vaccine there has been time to wait for a few months to observe the real-world clinical data coming from around the world that the vaccine is “performing as it did in the clinical trials”.
.
.
She says all vaccines cause allergic reactions, but severe ones are extremely rare and “we will be prepared for that”.
New Zealand’s Covid-19 immunisation programme is expected to take a full year, Bloomfield said.
The Pfizer vaccine is administered in two doses, with a three-week break.
She says all vaccines cause allergic reactions, but severe ones are extremely rare and “we will be prepared for that”.
New Zealand’s Covid-19 immunisation programme is expected to take a full year, Bloomfield said.
The Pfizer vaccine is administered in two doses, with a three-week break.
Comments
Post a Comment